BostonGene and Top-Ranked U.S. Hospital to Collaborate on Cancer Research Study

BostonGene to Identify Biomarkers of Response to Oncolytic Virus Therapy in Patients with Recurrent Malignant Glioma

WALTHAM, MA – September 15, 2020 – BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a scientific collaboration with Brigham and Women’s Hospital, a world-class academic medical center and a major teaching hospital of Harvard Medical School based in Boston, Massachusetts.

In this collaboration, BostonGene provides the analysis of whole transcriptome sequencing (RNA seq) data sets generated from tumor and blood samples from patients with recurrent glioblastoma (GBM) treated with an oncolytic virus as part of a Phase I clinical trial. As part of the effort, BostonGene correlation analysis aims to identify novel biomarkers of response to therapy. The collaboration will further demonstrate the powerful advantages of transcriptomic data analysis for prediction of the response to novel therapies for malignant brain tumors.

“We are very excited to enter into this collaboration with BostonGene in our efforts to fully understand the molecular underpinnings of responses to novel engineered viruses-based therapies,” said Ennio Antonio Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery at Brigham and Women’s Hospital. “This collaboration is another step in allowing us to make better individual treatment decisions for patients with GBM.”

“We’re honored to collaborate with Brigham and Women’s Hospital to demonstrate the clinical utility of BostonGene’s analytical tools that have been designed to improve diagnosis and treatment decisions for cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.  “We firmly believe that advanced computational analytics will better equip physicians as they identify personalized treatment plans.”

***

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

 

Media Contacts:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Announces Scientific Collaboration with Leading Cancer Center

Sophisticated Data Analytics to Predict Drug Response and Identify New Biomarkers in T-cell Lymphomas

WALTHAM, MA – August 4, 2020 – BostonGene Corporation (BostonGene), a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced its collaboration with The Weinstock Laboratory, a translational research program focused on novel therapeutics for lymphoid malignancies, at Dana-Farber Cancer Institute, Inc.  The collaboration aims to define predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas.

The Weinstock Laboratory is leading the research efforts to reveal mechanisms of response and resistance, and possible cause of adverse effects to Duvelisib (PI3K delta & gamma inhibitor) in patients with T-cell lymphomas (TCLs).  Their work is supported by the Leukemia and Lymphoma Society and by Verastem, the makers of Duvelisib.  In this collaboration, BostonGene provides advanced computational analytics of genomic, transcriptomic, proteomic and multiplex imaging data sets to predict drug response and identify new biomarkers.  BostonGene’s software uses a set of unique deconvolution algorithms that reveal cellular content of a tumor and surrounding microenvironment using transcriptome next generation sequencing (NGS) data, and image analysis algorithms to elucidate spatial parameters of tumor microenvironment  distribution using immunofluorescence (IF) imaging data.

“We are excited to collaborate with BostonGene,” said David Weinstock, MD, at Dana- Farber Cancer Institute, Inc. “Improving patient outcomes is our top priority and by partnering with BostonGene we hope to accurately predict which patients will benefit from treatment by identifying new biomarkers that could be useful for other patients with cancer.  The results have the potential to bring significant advantages to physicians as they make individual treatment decisions.”

“BostonGene is thrilled to collaborate with the Weinstock Laboratory at Dana- Farber Cancer Institute, Inc.” said Andrew Feinberg, President and CEO of BostonGene. “Our sophisticated analysis of RNAseq and exome sequencing will identify genomic and transcriptional alterations that could serve as predictive biomarkers of response and resistance to PI3 kinase inhibition that could ultimately improve patient outcomes. “

***

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

 

Media Contacts:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

 

BostonGene and NEC Collaborate to Analyze Cancer Patients in Clinical Trials

Integrated Genomic and Transcriptomic Next Generation Sequencing (NGS) Data to Reveal Cellular Content of Tumor Microenvironment

WALTHAM, MA, US and Tokyo, Japan – July 20, 2020 – BostonGene Corporation (BostonGene), a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, and NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies, today announced a collaboration to conduct cancer patient analysis treated under NEC’s clinical trials.  This collaboration brings together NEC’s artificial intelligence (AI)-driven approach to cancer immunotherapy with BostonGene’s sophisticated analytical tools.  

Under the terms of the collaboration agreement, BostonGene will perform tumor molecular profiling and microenvironment analysis for cancer patients identified in trials by NEC and or NEC affiliates across cancer types and disease stages.  The collaboration aims to provide molecular characterization of patient tumors for improvement of treatment response, both in clinical trial settings and beyond.

BostonGene’s solution integrates next-generation sequencing (NGS) obtained from a patient’s tumor with a reference cohort of data from patients with similar diagnosis, simultaneously analyzing tumor and tumor microenvironment activity.  The solution will identify all significant somatic alterations, protein expression, activity of tumor promoting and suppressing processes, tumor microenvironment cellular composition, tumor heterogeneity, tumor clonality, hereditary predisposition, viral infestation and pharmacogenomics among other molecular features.

“We are very excited to partner with NEC,” said Andrew Feinberg, President and CEO at BostonGene. “The collaboration between NEC and BostonGene demonstrates the combined commitment to delivering truly breakthrough therapies that identify personalized, effective treatments to dramatically improve patients’ chances for survival and quality of life.“ 

We are partnering with BostonGene because of its advanced patient analysis services,” said Osamu Fujikawa, Senior Vice President at NEC Corporation. “The strategic collaboration with BostonGene is reflective of our mission to improve cancer patient outcomes. BostonGene’s innovative data analytics platform combined with NEC’s cutting-edge AI technology gives us the tools needed to focus on advancing treatment options for cancer patients.”


About BostonGene Corporation 

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

About NEC Corporation 

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com

Media Contacts:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

NEC Corporation
Joseph Jasper
+81-3-3798-6511
j-jasper@nec.com

BostonGene to Present Three Abstracts at the 2020 American Association for Cancer Research (AACR) Annual Meeting

Abstracts Underscore the Importance of Advanced Molecular Profiling and Analytical Tools for Optimal Precision Medicine and Clinical treatment Design

WALTHAM, MA, June 3, 2020 — BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced that three abstracts were selected for poster presentations at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be conducted from June 22 – 24, 2020.

The presentations describe findings obtained by using BostonGene’s technologies and analytical tools designed to improve diagnosis and treatment decisions for cancer patients. Results include validation of bulk RNAseq utility for accurate reconstruction of tumor microenvironment and identification of four prominent microenvironment types conserved among solid tumors. Application of BostonGene computational tools lead to better understanding of the role of microenvironment compartments in tumor pathogenesis and supporting clinical decision making for the treatment of cancer.

“We are excited to present at the 2020 AACR Virtual Annual Meeting to share the clinical utility of the BostonGene solution and demonstrate how it improves diagnosis and treatment decisions for cancer patients,” said Andrew Feinberg, President and CEO of BostonGene.

Details of the poster presentations are as follows:

Abstract Number: 6168
Title: Integrated whole exome and transcriptome analyses of the tumor and microenvironment provide new opportunities for rational design of cancer therapy
Session: Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging
Poster: 4418
Presenter: Alexander Bagaev, BostonGene

BostonGene developed and validated a new analytic platform for multi-parametric analyses of malignant and nonmalignant tumor compartments using genomic and transcriptomic sequencing data. Application of BostonGene platform to more than 8,500 patient data sets revealed four types of tumor microenvironment (TME) that are conserved across cancer types and demonstrate high prognostic significance and differential response to immunotherapy. This novel Molecular-Functional (MF) portrait platform, involving analytic and visualization methods, provides a robust tool for prediction of response to immunotherapy and for future tailoring of personalized therapeutic combinations.

Abstract Number: 6997
Title:  Novel machine learning based deconvolution algorithm results in accurate description of tumor microenvironment from bulk RNAseq
Session: Machine Learning and Artificial Intelligence for Omics, Imaging, and Diagnostics
Poster: 853
Presenter: Alexander Bagaev, BostonGene

BostonGene developed a novel machine learning-based algorithm for cellular deconvolution of tumor microenvironment (TME) from bulk RNAseq data. This tool accurately reconstructs proportions of major immune and stromal cell populations, as well as T cell subtypes and M1 and M2 macrophages. Validation of BostonGene algorithm performance by comparison of flow cytometry, single cell RNAseq and bulk RNAseq analysis performed on samples from different tissues will be presented. The result demonstrates utility of bulk RNAseq for accurate and robust reconstruction of TME composition and paves the road for application of the BostonGene computational tool for support of clinical decision making for the treatment of cancer.

Research conducted with Massachusetts General Hospital

Abstract Number: 7544
Title: HER2 expression and M2-like tumor infiltrating macrophages associated with Cabazitaxel activity in gastric cancer
Session: Predictive Biomarkers for Treatment Efficacy 1
Poster: 2011
Presenter: Sandipto Sarkar, Weill Cornell Medicine

In the clinical study of cabazitaxel efficacy in gastric cancer, comprehensive whole exome sequencing (WES) and RNAseq data analysis identified genetic aberrations and tumor microenvironment signatures associated with favorable response. In particular, this analysis resulted in identification of two novel biomarkers, HER2 overexpression and M2-high tumor macrophage signature, both of which associated with improved outcomes. RNAseq-based deconvolution demonstrating M2 macrophages enrichment in patients with improved PFS, was further validated by immunohistochemistry using M1 and M2 macrophage-specific markers.

Research conducted with Weill Cornell Medicine

The e-poster website will be launched June 22, 2020, the first day of the AACR Virtual Annual Meeting II.  All e-posters will be made available for browsing on this date.

Additionally the abstracts will be published in an online-only Proceedings supplement to the AACR journal Cancer Research after the completion of the AACR Virtual Annual Meeting II.

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contacts:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Announces Acceptance of Seven Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States

WALTHAM, MA, May 19, 2020 — BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting.  All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

“We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGene‘s advanced precision medicine capabilities and our commitment to transform the lives of cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.

Details of abstract presentations are as follows:

Abstract Number: 8055*
Title: “Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Krystle Nomie, PhD, BostonGene
Poster: 388

Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: 6561*
Title: “Immune functional portraits of head and neck cancer using next generation sequencing”
Session: Head and Neck Cancer
Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Poster: 222

BostonGene’s comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.

Research conducted with Massachusetts General Hospital

Abstract Number: 8054*
Title: “Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Cody Ramirez at Washington University in St Louis
Poster: 387

Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.

Research conducted with Washington University in St Louis

Abstract Number: e20065
Title: “Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma”
First Author: Krystle Nomie, PhD, BostonGene

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: e21026
Title: “Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies”
First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Research conducted with Massachusetts General Hospital

Abstract Number: e17106
Title: “Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma”
First Author: James Hsieh, MD, PhD at Washington University in St. Louis

Research conducted with Washington University in St Louis

Abstract Number:  e17506
Title: “Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome”
First Author: Eric H. Kim, MD at Washington University in St. Louis

Research conducted with Washington University in St Louis

*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contacts:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

 

BostonGene and Washington University in St. Louis Collaborate on Kidney Cancer Research

Ongoing Studies to Analyze Tumor and Tumor Microenvironment Molecular Composition of Renal Cell Carcinoma

WALTHAM, MA – April 30, 2020 – BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced it has expanded its research collaboration with Washington University in St. Louis to study renal cell carcinoma (RCC).

This collaboration will evaluate the role tumor microenvironment in RCC progression and treatment response for early stage, as well as metastatic RCC patients treated with approved immune checkpoint inhibitors (ICIs) and targeted agents. As part of this program, BostonGene will perform integrated analysis of multi-platform data generated by multiplex immunofluorescence microscopy (MxIF), whole exome sequencing (WES), whole transcriptome sequencing (RNA-seq), single nuclei RNA-seq (snRNA-seq), whole genome bisulfite sequencing (WGBS), cytometry (CyTOF) and conventional clinical tests like tumor PD-L1 expression, blood cell count and biochemistry.

BostonGene’s software uses a set of unique deconvolution algorithms that reveal cellular content of a tumor and surrounding microenvironment using transcriptome next generation sequencing (NGS) data. Addition of the image analysis component elucidates cellular architecture and spatial localization of tumor, immune and stromal cells. High concordance observed among these technologies suggests that tumor NGS analysis involving WES/RNAseq using BostonGene analytical tools may be utilized for treatment decision support and can be clinically applicable for ccRCC.

Although some RCC patients respond to targeted or immunotherapies, treatment support tools that allow better prediction of response, remain an unmet need.  BostonGene’s comprehensive analysis of RCC tumors and their microenvironment brings an optimal personalized solution predicting the benefits of a particular treatment regime based on the integrated analysis of NGS, imaging and other molecular-level data collected from a primary tumor, metastatic sites and circulating blood.

“We’re collaborating with BostonGene to evaluate how its technology, which includes the integrated analysis of NGS and Multiplex immunofluorescence imaging, can be applied to help make treatment decisions for individual patients with renal cell carcinoma and ultimately improve patient outcomes,” said James Hsieh, MD, PhD, a medical oncologist and Professor of Medicine at Washington University School of Medicine in St Louis.

“We are excited to expand our partnership with Washington University to develop personalized solutions for kidney cancer patients by integrating molecular and clinical information about the individual patient disease with prior knowledge base accumulated from patients with similar diagnosis”, said Andrew Feinberg, President & CEO at BostonGene.

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contacts:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Announces Appointment of Nathan Fowler, M.D., as Chief Medical Officer

Fowler to Provide Strategic Direction for BostonGene in its Mission to Cure Cancer

WALTHAM, MA – February 27, 2020 – BostonGene Corporation, a biomedical software company, today announced the appointment of Nathan Fowler, M.D., to the newly created position of Chief Medical Officer (CMO). Dr. Fowler joins BostonGene as it moves into the advanced stages of commercializing its personalized medicine solutions.

Dr. Fowler brings more than 20 years of patient care experience to BostonGene—most recently as a Professor of Medicine in the Department of Lymphoma/Myeloma at the University of Texas, MD Anderson Cancer Center. In addition to his role as CMO at BostonGene, Dr. Fowler will retain his affiliation with MD Anderson, continuing his involvement in the treatment of lymphoma patients while furthering his clinical research.

“We’re thrilled to welcome Dr. Fowler to BostonGene as a senior member of our management team,” said Andrew Feinberg, President and CEO at BostonGene. “His extensive experience researching and developing new therapies, combined with his commitment to discovering innovative solutions to treat patients, is invaluable to BostonGene as we continue to develop our solutions designed to treat the person, not the diagnosis.”

“I am honored to join BostonGene as its Chief Medical Officer,” said Nathan Fowler, M.D. “I have devoted my entire medical career to finding innovative solutions for cancer treatment, and I firmly believe BostonGene’s solution is fundamentally going to change how we treat cancer patients. I look forward to working with cancer centers from around the globe to drive change and improve the outcomes of all patients battling cancer.”

Dr. Fowler received his medical degree from the University of Texas, having completed his internship and residency there as well. He went on to complete a fellowship in hematology/oncology at Georgetown University Hospital in Washington D.C. At MD Anderson Cancer Center, Dr. Fowler focused on developing groundbreaking new therapies for cancer patients and led the clinical research program for nearly ten years. He is considered one of the world’s foremost experts in drug development for blood cancers, and his direct work led to the FDA approval of several novel agents in lymphoma. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination.

Dr. Fowler has published over 150 articles in peer-reviewed journals as well as numerous textbooks on innovative approaches to cancer therapy. Prior to his work in medicine, Dr. Fowler served in the U.S. Army as a nuclear, biological and chemical defense specialist. In addition, he serves as the President and Founder of Halo House Foundation, a non-profit organization providing housing to blood cancer patients receiving treatment.

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contacts:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Announces Scientific Collaboration with the Vaccine and Immunotherapy Center at Massachusetts General Hospital

Sophisticated Data Analytics to Validate Tumor Molecular Profiles in Cancer Patients

WALTHAM, MA – January 14, 2020 – BostonGene Corporation (BostonGene), a biomedical software company, today announced its collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.

BostonGene performs a computational analysis of a patient’s genomics and transcriptomics data from solid tumors including Lung Cancer and Head and Neck Cancer. In parallel, MGH VIC team conducts mass cytometry analysis of tissue of same patients. A correlation analysis is then employed to demonstrate the power of the computational algorithms in the assessment of the intratumoral cellular composition including stromal and immune components. The results of this collaboration highlight the powerful advantage of NGS data analysis in comparison to conventional techniques to more fully characterize the tumor.

Using small amounts of tissue, BostonGene provides an accurate, patient tailored report for physicians. The report includes a visually-appealing and self-explanatory tumor schematics, called MF Portrait™, depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

“Our collaboration with BostonGene is aimed at understanding the pathogenesis of each person’s cancer and ultimately having a positive impact on patient care by enabling personalized cancer treatments,” said Mark Poznansky, MD, PhD, at Massachusetts General Hospital.

“BostonGene provides the solution necessary for oncologists to evaluate NGS data in combination with all relevant clinical knowledge to determine the best personalized care for the individual patient,” said Andrew Feinberg, President and CEO of BostonGene. “We are excited to collaborate with VIC at MGH to demonstrate how our unique solution for tailored treatment options improves outcomes for cancer patients.”

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contacts:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene and Weill Cornell Medicine Reveal Results from Cancer Microenvironment Study

ORLANDO, FL , December 9, 2019 – BostonGene Corporation (BostonGene), a Boston-based biomedical software company, presented results of its recent cancer microenvironment study during the 61st American Society of Hematology Annual Meeting and Exposition held on December 7-10, 2019. The research study examined the role of the tumor microenvironment of Diffuse Large B-Cell Lymphoma (DLBCL).

The study, conducted as part of BostonGene’s collaboration with Weill Cornell Medicine, combined whole exome and transcriptome analyses from an integrated cohort of 3,026 DLBCL patients. The cohort includes publically available data as well as prospective patients.

The study revealed that a new classification based on the tumor microenvironment is associated with clinical outcomes independently of existing molecular subtypes. Computationally predicted results demonstrated a strong correlation with response therapy obtained in murine DLBCL models for subtypes based on stromal, immune and malignant composition.

“Improving treatment outcomes for individual DLBCL patients by integrated analysis of large-scale next-generation sequencing (NGS) data including somatic variants and gene expression changes in the tumor and the tumor microenvironment is our top priority,” said Leandro Cerchietti, M.D., Associate Professor of Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “These promising findings bring us one step closer to achieving that goal.”

“We are proud to collaborate with Weill Cornell Medicine to provide advanced computational analytics for the integration of big data sets generated for each patient,” said Andrew Feinberg, President and CEO of BostonGene. “We look forward to continuing our collaboration to further identify the best treatment options for cancer patients.”

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contact:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene to Present Multiple Abstracts at the 2019 American Society of Hematology (ASH) Annual Meeting

WALTHAM, MA, November 21, 2019 — BostonGene Corporation (BostonGene), a Boston-based biomedical software company, today announced that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida. In addition, BostonGene will exhibit at booth #152 in Hall B.

The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.

POSTER PRESENTATION

Sunday, December 8, 2019: 6:00 PM – 8:00 PM in Hall B, Level 2

ORAL PRESENTATION

Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2

Additional information on abstracts for ASH Annual Meeting can found here: http://www.hematology.org/Annual-Meeting/.

“We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year’s ASH event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients’ chances for survival,” said Andrew Feinberg, President & CEO at BostonGene.

About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Media Contact:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com